Last updated on February 2018

Phase 3 Study to Compare Safety and Efficacy of Smoflipid 20% to Intralipid 20% in Hospitalized Neonates and Infants


Brief description of study

To show the superiority in safety of Smoflipid over Intralipid as measured by the number of study patients in each treatment group with conjugated bilirubin exceeding 2 mg/dL during the first 28 days of study treatment, confirmed by a second sample collected 7 days after the first sample.

Clinical Study Identifier: NCT02579265

Contact Investigators or Research Sites near you

Start Over

John F Stover, MD

Steven & Alexandra Cohen Children's Medical Center of NY
New York, NY United States
  Connect »